cd3 t cell Search Results


94
R&D Systems magcellect mouse cd3 t cell isolation kit
Magcellect Mouse Cd3 T Cell Isolation Kit, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/magcellect mouse cd3 t cell isolation kit/product/R&D Systems
Average 94 stars, based on 1 article reviews
magcellect mouse cd3 t cell isolation kit - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier

94
Vazyme Biotech Co themousecd8 t cell isolation kit
Themousecd8 T Cell Isolation Kit, supplied by Vazyme Biotech Co, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/themousecd8 t cell isolation kit/product/Vazyme Biotech Co
Average 94 stars, based on 1 article reviews
themousecd8 t cell isolation kit - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier

94
R&D Systems magcellect human cd3 t cell isolation kit
Magcellect Human Cd3 T Cell Isolation Kit, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/magcellect human cd3 t cell isolation kit/product/R&D Systems
Average 94 stars, based on 1 article reviews
magcellect human cd3 t cell isolation kit - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier

92
R&D Systems human cd3 t cells
Human Cd3 T Cells, supplied by R&D Systems, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human cd3 t cells/product/R&D Systems
Average 92 stars, based on 1 article reviews
human cd3 t cells - by Bioz Stars, 2026-03
92/100 stars
  Buy from Supplier

93
R&D Systems mouse cd3 t cell column enrichment kit
AAV2/8-insulin-based therapy elicits a cellular immune response against the vector and the transgene in NOD diabetic mice. Livers of NOD mice treated with AAV2/8-HLP-hINSco (indicated with AAV2/8) show signs of T cell infiltration observed in pre-diabetic NOD mouse pancreata. a Pancreas sections from a 8-week-old control NOD female pancreas ( a , top panel), a 30-day AAV2/8-insulin-treated C57BL/6 ( a , middle panel) and a 30-day AAV2/8-insulin-treated NOD ( a , bottom panel) were stained for insulin (red) and glucagon (green), and <t>CD3</t> (yellow) to show β-cell destruction in treated mice. b Livers from AAV2/8-HLP-hINSco -injected C57BL/6 ( b , left) and NOD ( b , right) mice were stained for insulin and CD3 to test for T cell infiltration. c Livers from AAV2/8-HLP-hINSco-injected NOD mice were stained for insulin and CD8. Blue shows nuclear DAPI staining. Scale bar 50 μm. d, e Ex vivo stimulated splenocytes from AAV2/8-HLP-hINSco -treated NOD mice and C57BL/6 controls for IFN-γ ELISPOT assay. Cells from NOD and C57BL/6 mice were harvested after 30 days ( d ) or more than 200 days ( e ) from the day of the injection of the AAV2/8-insulin vector. Cells were stimulated in vitro for 40 h with CD8 + immunodominant peptides (either InsB 15–23 peptide for NOD or insulin K b -restricted epitope A 12–21 containing peptide for C57BL/6) or the AAV8 capsid-specific CD8 + T cell peptide NSLANPGIA and the number of resulting IFN-γ spots was counted with an ELISPOT reader. f Levels of anti-inflammatory cytokines in NOD mice compared to C57BL/6. Splenocytes from C57BL/6 and NOD mice were harvested at the end of a 30-day treatment with AAV2/8-HLP-hINSco 5 × 10 9 vg and stimulated with PMA/Iono for 48 h. Supernatants were then collected and tested for IL-10 production. g Mouse anti-AAV8 ELISA performed on blood plasma of diabetic, healthy and 5 × 10 9 vg AAV2/8-HLP-hINSco-treated NOD and C57BL/6 mice. Treated mice were tested for anti-AAV8 antibodies 30 days after the beginning of the therapy. The absorbances at 405 nm correlate with the concentration of the antibody. *( p ≤ 0.05), **( p ≤ 0.01), ***( p ≤ 0.001), unpaired Student’s t -test. Data shown are expressed as mean ± SE and are representative of two independent experiments
Mouse Cd3 T Cell Column Enrichment Kit, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mouse cd3 t cell column enrichment kit/product/R&D Systems
Average 93 stars, based on 1 article reviews
mouse cd3 t cell column enrichment kit - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier

90
STEMCELL Technologies Inc stemsep human cd3+ t cell depletion
AAV2/8-insulin-based therapy elicits a cellular immune response against the vector and the transgene in NOD diabetic mice. Livers of NOD mice treated with AAV2/8-HLP-hINSco (indicated with AAV2/8) show signs of T cell infiltration observed in pre-diabetic NOD mouse pancreata. a Pancreas sections from a 8-week-old control NOD female pancreas ( a , top panel), a 30-day AAV2/8-insulin-treated C57BL/6 ( a , middle panel) and a 30-day AAV2/8-insulin-treated NOD ( a , bottom panel) were stained for insulin (red) and glucagon (green), and <t>CD3</t> (yellow) to show β-cell destruction in treated mice. b Livers from AAV2/8-HLP-hINSco -injected C57BL/6 ( b , left) and NOD ( b , right) mice were stained for insulin and CD3 to test for T cell infiltration. c Livers from AAV2/8-HLP-hINSco-injected NOD mice were stained for insulin and CD8. Blue shows nuclear DAPI staining. Scale bar 50 μm. d, e Ex vivo stimulated splenocytes from AAV2/8-HLP-hINSco -treated NOD mice and C57BL/6 controls for IFN-γ ELISPOT assay. Cells from NOD and C57BL/6 mice were harvested after 30 days ( d ) or more than 200 days ( e ) from the day of the injection of the AAV2/8-insulin vector. Cells were stimulated in vitro for 40 h with CD8 + immunodominant peptides (either InsB 15–23 peptide for NOD or insulin K b -restricted epitope A 12–21 containing peptide for C57BL/6) or the AAV8 capsid-specific CD8 + T cell peptide NSLANPGIA and the number of resulting IFN-γ spots was counted with an ELISPOT reader. f Levels of anti-inflammatory cytokines in NOD mice compared to C57BL/6. Splenocytes from C57BL/6 and NOD mice were harvested at the end of a 30-day treatment with AAV2/8-HLP-hINSco 5 × 10 9 vg and stimulated with PMA/Iono for 48 h. Supernatants were then collected and tested for IL-10 production. g Mouse anti-AAV8 ELISA performed on blood plasma of diabetic, healthy and 5 × 10 9 vg AAV2/8-HLP-hINSco-treated NOD and C57BL/6 mice. Treated mice were tested for anti-AAV8 antibodies 30 days after the beginning of the therapy. The absorbances at 405 nm correlate with the concentration of the antibody. *( p ≤ 0.05), **( p ≤ 0.01), ***( p ≤ 0.001), unpaired Student’s t -test. Data shown are expressed as mean ± SE and are representative of two independent experiments
Stemsep Human Cd3+ T Cell Depletion, supplied by STEMCELL Technologies Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/stemsep human cd3+ t cell depletion/product/STEMCELL Technologies Inc
Average 90 stars, based on 1 article reviews
stemsep human cd3+ t cell depletion - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
Nichirei Corporation cd3 t cell markers sp3 antibody
AAV2/8-insulin-based therapy elicits a cellular immune response against the vector and the transgene in NOD diabetic mice. Livers of NOD mice treated with AAV2/8-HLP-hINSco (indicated with AAV2/8) show signs of T cell infiltration observed in pre-diabetic NOD mouse pancreata. a Pancreas sections from a 8-week-old control NOD female pancreas ( a , top panel), a 30-day AAV2/8-insulin-treated C57BL/6 ( a , middle panel) and a 30-day AAV2/8-insulin-treated NOD ( a , bottom panel) were stained for insulin (red) and glucagon (green), and <t>CD3</t> (yellow) to show β-cell destruction in treated mice. b Livers from AAV2/8-HLP-hINSco -injected C57BL/6 ( b , left) and NOD ( b , right) mice were stained for insulin and CD3 to test for T cell infiltration. c Livers from AAV2/8-HLP-hINSco-injected NOD mice were stained for insulin and CD8. Blue shows nuclear DAPI staining. Scale bar 50 μm. d, e Ex vivo stimulated splenocytes from AAV2/8-HLP-hINSco -treated NOD mice and C57BL/6 controls for IFN-γ ELISPOT assay. Cells from NOD and C57BL/6 mice were harvested after 30 days ( d ) or more than 200 days ( e ) from the day of the injection of the AAV2/8-insulin vector. Cells were stimulated in vitro for 40 h with CD8 + immunodominant peptides (either InsB 15–23 peptide for NOD or insulin K b -restricted epitope A 12–21 containing peptide for C57BL/6) or the AAV8 capsid-specific CD8 + T cell peptide NSLANPGIA and the number of resulting IFN-γ spots was counted with an ELISPOT reader. f Levels of anti-inflammatory cytokines in NOD mice compared to C57BL/6. Splenocytes from C57BL/6 and NOD mice were harvested at the end of a 30-day treatment with AAV2/8-HLP-hINSco 5 × 10 9 vg and stimulated with PMA/Iono for 48 h. Supernatants were then collected and tested for IL-10 production. g Mouse anti-AAV8 ELISA performed on blood plasma of diabetic, healthy and 5 × 10 9 vg AAV2/8-HLP-hINSco-treated NOD and C57BL/6 mice. Treated mice were tested for anti-AAV8 antibodies 30 days after the beginning of the therapy. The absorbances at 405 nm correlate with the concentration of the antibody. *( p ≤ 0.05), **( p ≤ 0.01), ***( p ≤ 0.001), unpaired Student’s t -test. Data shown are expressed as mean ± SE and are representative of two independent experiments
Cd3 T Cell Markers Sp3 Antibody, supplied by Nichirei Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cd3 t cell markers sp3 antibody/product/Nichirei Corporation
Average 90 stars, based on 1 article reviews
cd3 t cell markers sp3 antibody - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
Brehm GmbH cd3 t-cell depletion
A CD127 + and CD127 − cells from Lin − CD56 − population after gating on lymphoid, singlet, live, CD45 + cells of PBMCs. Lineage (Lin) markers include antibodies against: <t>CD3,</t> CD4, TCRαβ, TCRγδ, CD19, CD20, CD22, CD34, FcεRIα, CD11c, CD303, CD123, CD1a, and CD14. B Heatmap of differentially expressed genes by RNA‐Seq, sorted Lin − CD56 − CD16 − CD127 + versus Lin − CD56 − CD16 − CD127 − cells, from PBMCs of five donors (log2 fold change > 1, P adj < 0.01 determined by DESeq2, the postsort profiles are shown in Appendix Fig ). C Normalized counts of Lin − CD56 − CD127 + (red) and Lin − CD56 − CD127 − (blue) cell‐related genes from (B) by DESeq2 ( n = 5). D, E Reactome analysis based on enriched transcripts of Lin − CD56 − CD127 + cells (D) or Lin − CD56 − CD127 − cells (E). F Gating of Lin − CD56 hi NK, Lin − CD56 dim NK, Lin − CD56 − NK cells, and Lin − CD56 − CD16 − CD127 + ILCs. G The indicated populations in (F) were detected with isotype controls or antibodies against TBX21, CRTH2, and RORγT. Data information: All data were generated using blood from healthy HIV‐1‐negative donors.
Cd3 T Cell Depletion, supplied by Brehm GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cd3 t-cell depletion/product/Brehm GmbH
Average 90 stars, based on 1 article reviews
cd3 t-cell depletion - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
Becton Dickinson cd3-t cell receptor
Monoclonal mouse anti-human antibodies (MoAbs) used in this study
Cd3 T Cell Receptor, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cd3-t cell receptor/product/Becton Dickinson
Average 90 stars, based on 1 article reviews
cd3-t cell receptor - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
STEMCELL Technologies Inc cd3+ t cell separation reagent kit
Monoclonal mouse anti-human antibodies (MoAbs) used in this study
Cd3+ T Cell Separation Reagent Kit, supplied by STEMCELL Technologies Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cd3+ t cell separation reagent kit/product/STEMCELL Technologies Inc
Average 90 stars, based on 1 article reviews
cd3+ t cell separation reagent kit - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
Bio X Cell human cd3 + t cells
Monoclonal mouse anti-human antibodies (MoAbs) used in this study
Human Cd3 + T Cells, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human cd3 + t cells/product/Bio X Cell
Average 90 stars, based on 1 article reviews
human cd3 + t cells - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
CEM Corporation cell surface cd3 t-cell receptor complex
Monoclonal mouse anti-human antibodies (MoAbs) used in this study
Cell Surface Cd3 T Cell Receptor Complex, supplied by CEM Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cell surface cd3 t-cell receptor complex/product/CEM Corporation
Average 90 stars, based on 1 article reviews
cell surface cd3 t-cell receptor complex - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


AAV2/8-insulin-based therapy elicits a cellular immune response against the vector and the transgene in NOD diabetic mice. Livers of NOD mice treated with AAV2/8-HLP-hINSco (indicated with AAV2/8) show signs of T cell infiltration observed in pre-diabetic NOD mouse pancreata. a Pancreas sections from a 8-week-old control NOD female pancreas ( a , top panel), a 30-day AAV2/8-insulin-treated C57BL/6 ( a , middle panel) and a 30-day AAV2/8-insulin-treated NOD ( a , bottom panel) were stained for insulin (red) and glucagon (green), and CD3 (yellow) to show β-cell destruction in treated mice. b Livers from AAV2/8-HLP-hINSco -injected C57BL/6 ( b , left) and NOD ( b , right) mice were stained for insulin and CD3 to test for T cell infiltration. c Livers from AAV2/8-HLP-hINSco-injected NOD mice were stained for insulin and CD8. Blue shows nuclear DAPI staining. Scale bar 50 μm. d, e Ex vivo stimulated splenocytes from AAV2/8-HLP-hINSco -treated NOD mice and C57BL/6 controls for IFN-γ ELISPOT assay. Cells from NOD and C57BL/6 mice were harvested after 30 days ( d ) or more than 200 days ( e ) from the day of the injection of the AAV2/8-insulin vector. Cells were stimulated in vitro for 40 h with CD8 + immunodominant peptides (either InsB 15–23 peptide for NOD or insulin K b -restricted epitope A 12–21 containing peptide for C57BL/6) or the AAV8 capsid-specific CD8 + T cell peptide NSLANPGIA and the number of resulting IFN-γ spots was counted with an ELISPOT reader. f Levels of anti-inflammatory cytokines in NOD mice compared to C57BL/6. Splenocytes from C57BL/6 and NOD mice were harvested at the end of a 30-day treatment with AAV2/8-HLP-hINSco 5 × 10 9 vg and stimulated with PMA/Iono for 48 h. Supernatants were then collected and tested for IL-10 production. g Mouse anti-AAV8 ELISA performed on blood plasma of diabetic, healthy and 5 × 10 9 vg AAV2/8-HLP-hINSco-treated NOD and C57BL/6 mice. Treated mice were tested for anti-AAV8 antibodies 30 days after the beginning of the therapy. The absorbances at 405 nm correlate with the concentration of the antibody. *( p ≤ 0.05), **( p ≤ 0.01), ***( p ≤ 0.001), unpaired Student’s t -test. Data shown are expressed as mean ± SE and are representative of two independent experiments

Journal: Gene Therapy

Article Title: Immunosuppression overcomes insulin- and vector-specific immune responses that limit efficacy of AAV2/8-mediated insulin gene therapy in NOD mice

doi: 10.1038/s41434-018-0052-5

Figure Lengend Snippet: AAV2/8-insulin-based therapy elicits a cellular immune response against the vector and the transgene in NOD diabetic mice. Livers of NOD mice treated with AAV2/8-HLP-hINSco (indicated with AAV2/8) show signs of T cell infiltration observed in pre-diabetic NOD mouse pancreata. a Pancreas sections from a 8-week-old control NOD female pancreas ( a , top panel), a 30-day AAV2/8-insulin-treated C57BL/6 ( a , middle panel) and a 30-day AAV2/8-insulin-treated NOD ( a , bottom panel) were stained for insulin (red) and glucagon (green), and CD3 (yellow) to show β-cell destruction in treated mice. b Livers from AAV2/8-HLP-hINSco -injected C57BL/6 ( b , left) and NOD ( b , right) mice were stained for insulin and CD3 to test for T cell infiltration. c Livers from AAV2/8-HLP-hINSco-injected NOD mice were stained for insulin and CD8. Blue shows nuclear DAPI staining. Scale bar 50 μm. d, e Ex vivo stimulated splenocytes from AAV2/8-HLP-hINSco -treated NOD mice and C57BL/6 controls for IFN-γ ELISPOT assay. Cells from NOD and C57BL/6 mice were harvested after 30 days ( d ) or more than 200 days ( e ) from the day of the injection of the AAV2/8-insulin vector. Cells were stimulated in vitro for 40 h with CD8 + immunodominant peptides (either InsB 15–23 peptide for NOD or insulin K b -restricted epitope A 12–21 containing peptide for C57BL/6) or the AAV8 capsid-specific CD8 + T cell peptide NSLANPGIA and the number of resulting IFN-γ spots was counted with an ELISPOT reader. f Levels of anti-inflammatory cytokines in NOD mice compared to C57BL/6. Splenocytes from C57BL/6 and NOD mice were harvested at the end of a 30-day treatment with AAV2/8-HLP-hINSco 5 × 10 9 vg and stimulated with PMA/Iono for 48 h. Supernatants were then collected and tested for IL-10 production. g Mouse anti-AAV8 ELISA performed on blood plasma of diabetic, healthy and 5 × 10 9 vg AAV2/8-HLP-hINSco-treated NOD and C57BL/6 mice. Treated mice were tested for anti-AAV8 antibodies 30 days after the beginning of the therapy. The absorbances at 405 nm correlate with the concentration of the antibody. *( p ≤ 0.05), **( p ≤ 0.01), ***( p ≤ 0.001), unpaired Student’s t -test. Data shown are expressed as mean ± SE and are representative of two independent experiments

Article Snippet: T cells were isolated with the Mouse CD3 + T cell column enrichment kit (R&D) and plated at the concentration of 3 × 10 5 cells/ 50 μl/well, and analysed using the Mitostress kit (Agilent technologies) according to the manufacturers’ instructions.

Techniques: Plasmid Preparation, Staining, Injection, Ex Vivo, Enzyme-linked Immunospot, In Vitro, Enzyme-linked Immunosorbent Assay, Concentration Assay

A CD127 + and CD127 − cells from Lin − CD56 − population after gating on lymphoid, singlet, live, CD45 + cells of PBMCs. Lineage (Lin) markers include antibodies against: CD3, CD4, TCRαβ, TCRγδ, CD19, CD20, CD22, CD34, FcεRIα, CD11c, CD303, CD123, CD1a, and CD14. B Heatmap of differentially expressed genes by RNA‐Seq, sorted Lin − CD56 − CD16 − CD127 + versus Lin − CD56 − CD16 − CD127 − cells, from PBMCs of five donors (log2 fold change > 1, P adj < 0.01 determined by DESeq2, the postsort profiles are shown in Appendix Fig ). C Normalized counts of Lin − CD56 − CD127 + (red) and Lin − CD56 − CD127 − (blue) cell‐related genes from (B) by DESeq2 ( n = 5). D, E Reactome analysis based on enriched transcripts of Lin − CD56 − CD127 + cells (D) or Lin − CD56 − CD127 − cells (E). F Gating of Lin − CD56 hi NK, Lin − CD56 dim NK, Lin − CD56 − NK cells, and Lin − CD56 − CD16 − CD127 + ILCs. G The indicated populations in (F) were detected with isotype controls or antibodies against TBX21, CRTH2, and RORγT. Data information: All data were generated using blood from healthy HIV‐1‐negative donors.

Journal: The EMBO Journal

Article Title: Transcriptional and chromatin profiling of human blood innate lymphoid cell subsets sheds light on HIV ‐1 pathogenesis

doi: 10.15252/embj.2023114153

Figure Lengend Snippet: A CD127 + and CD127 − cells from Lin − CD56 − population after gating on lymphoid, singlet, live, CD45 + cells of PBMCs. Lineage (Lin) markers include antibodies against: CD3, CD4, TCRαβ, TCRγδ, CD19, CD20, CD22, CD34, FcεRIα, CD11c, CD303, CD123, CD1a, and CD14. B Heatmap of differentially expressed genes by RNA‐Seq, sorted Lin − CD56 − CD16 − CD127 + versus Lin − CD56 − CD16 − CD127 − cells, from PBMCs of five donors (log2 fold change > 1, P adj < 0.01 determined by DESeq2, the postsort profiles are shown in Appendix Fig ). C Normalized counts of Lin − CD56 − CD127 + (red) and Lin − CD56 − CD127 − (blue) cell‐related genes from (B) by DESeq2 ( n = 5). D, E Reactome analysis based on enriched transcripts of Lin − CD56 − CD127 + cells (D) or Lin − CD56 − CD127 − cells (E). F Gating of Lin − CD56 hi NK, Lin − CD56 dim NK, Lin − CD56 − NK cells, and Lin − CD56 − CD16 − CD127 + ILCs. G The indicated populations in (F) were detected with isotype controls or antibodies against TBX21, CRTH2, and RORγT. Data information: All data were generated using blood from healthy HIV‐1‐negative donors.

Article Snippet: UCB was processed as previously described and underwent CD3 T‐cell depletion (Brehm et al , ).

Techniques: RNA Sequencing, Generated

Journal: The EMBO Journal

Article Title: Transcriptional and chromatin profiling of human blood innate lymphoid cell subsets sheds light on HIV ‐1 pathogenesis

doi: 10.15252/embj.2023114153

Figure Lengend Snippet:

Article Snippet: UCB was processed as previously described and underwent CD3 T‐cell depletion (Brehm et al , ).

Techniques: Control, Sequencing, Cell Stimulation, Multiplex Assay, Purification, Cell Isolation, Software

Monoclonal mouse anti-human antibodies (MoAbs) used in this study

Journal:

Article Title: Inflammatory cytokines in small intestinal mucosa of patients with potential coeliac disease

doi: 10.1046/j.1365-2249.2002.01798.x

Figure Lengend Snippet: Monoclonal mouse anti-human antibodies (MoAbs) used in this study

Article Snippet: CD3 , CD3-T cell receptor , 1:200 , Becton-Dickinson, San Jose, CA, USA.

Techniques: